Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Zozaya, Néboa (Universidad de Las Palmas de Gran Canaria)
Abdalla, Fernando (Weber (Madrid))
Alfonso Zamora, Santiago (Psoriasis and Psoriatic Arthritis Patient and Family Association)
Balea Filgueiras, Jesus (Complejo Hospitalario Universitario de Ferrol)
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Delgado Sánchez, Olga (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València))
García-Ruiz, Antonio (Instituto de Investigación Biomédica de Málaga)
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid))
Manfredi, Antonio (Psoriasis and Psoriatic Arthritis Patient and Family Association)
Martínez Olmos, José (Escuela Andaluza de Salud Pública (Granada, Andalusia))
Morales de Los Ríos Luna, Paloma (Hospital General Universitario Gregorio Marañón)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Ros Abarca, Sandra (Institut d'Investigació Biomèdica Sant Pau)
Hidalgo-Vega, Álvaro (Universidad de Castilla-La Mancha)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Background: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. Research design and methods: The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Results: Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Conclusions: Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.
Note:	This project was funded by UCB Pharma S.A.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Bimekizumab ; Biologics ; MCDA ; Moderate-to-severe ; Multi-criteria decision analysis ; Psoriasis
Published in:	Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22 Núm. 6 (2022) , p. 941-953, ISSN 1744-8379

DOI: 10.1080/14737167.2022.2063842
PMID: 35404728

15 p, 3.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles